Jenny Jiao

TL;DR: In this paper, the safety and efficacy of dexamethasone intravitreal implant (DEX implant; OZURDEX, Allergan, Inc., Irvine, CA) compared with sham in eyes with vision loss due to macular edema (ME) associated with BRVO or central retinal vein occlusion (CRVO).

TL;DR: Among patients with macular edema owing to BRVO or CRVO, single and repeated treatment with DEX implant had a favorable safety profile over 12 months.

TL;DR: Abicipar Q8 and Q12 were both noninferior to ranibizumab Q4 in the primary end point of stable vision at week 52, and quarterly and Q8 abicipar reduce nAMD disease and treatment burden compared with monthly treatment.

TL;DR: Both DEX implant and ranibizumab were well tolerated and improved BCVA and anatomic outcomes in patients with DME and both met the a priori criterion for noninferiority to ranibzumab in average change from baseline BCVA over 12 months.

TL;DR: DEX had a favorable safety profile and provided clinically significant benefit in a Chinese patient population with RVO and visual and anatomic outcomes were improved with DEX relative to sham for 3–4 months after a single implant.